# Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

> **NCT02113878** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 23 (actual)

## Conditions studied

- Carcinoma, Squamous Cell of Head and Neck
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Hypopharyngeal Cancer
- Early Invasive Cervical Squamous Cell Carcinoma
- Carcinoma of Larynx
- Cancer of Nasopharynx

## Interventions

- **DRUG:** BKM120
- **DRUG:** Cisplatin
- **RADIATION:** Intensity-modulated radiotherapy (IMRT)

## Key facts

- **NCT ID:** NCT02113878
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-29
- **Primary completion:** 2019-12-06
- **Final completion:** 2022-01-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113878, "Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02113878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*